Clinical Trials Logo

Filter by:
NCT ID: NCT00240643 Completed - Atrial Fibrillation Clinical Trials

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.

NCT ID: NCT00240383 Completed - Clinical trials for Diabetes Mellitus II

Dose Ranging Study With LT, Monotherapy, PPAR

Start date: May 2002
Phase: Phase 2/Phase 3
Study type: Interventional

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

NCT ID: NCT00240331 Completed - Renal Failure Clinical Trials

AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.

NCT ID: NCT00239967 Completed - Obesity Clinical Trials

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

ADAGIO-lipids
Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese patients with atherogenic dyslipidemia (low HDL and/or high TG plasma levels). The secondary objectives are to evaluate specific metabolic parameters, visceral fat (in selected sites), safety and tolerability of rimonabant 20 mg.

NCT ID: NCT00239681 Terminated - Clinical trials for Elevated High-sensitivity C-Reactive Protein (hsCRP)

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Start date: February 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.

NCT ID: NCT00237133 Completed - Clinical trials for Locally Advanced Breast Cancer

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

PREDICT
Start date: March 2003
Phase: Phase 4
Study type: Interventional

Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)

NCT ID: NCT00233792 Completed - Clinical trials for Coronary Artery Disease

FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent

Start date: December 1999
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single center, non-randomized study. Patients will be treated with the sirolimus coated Bx VELOCITY Balloon-Expandable Stent mounted on the Raptor OTW SDS. Patients will have a repeat angiography at four months and will be followed for twelve months post-procedure.

NCT ID: NCT00233779 Completed - Clinical trials for Coronary Artery Disease

Evaluation of Sirolimus-Eluting, Heparin-Coated CoCr Stent in the Treatment of de Novo Coronary Artery Lesions in Small Vessels(EVOLUTION)

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the performance and safety of a sirolimus-eluting, heparin-coated, cobalt chromium balloon-expandable stent (Small Vessel Stent) in patients with de novo native coronary artery lesions in small vessels as compared to historical data from small vessel patients in the RAVEL trial receiving the Sirolimus-eluting Bx VELOCITY™ stent.

NCT ID: NCT00233766 Completed - Clinical trials for Coronary Artery Disease

Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)

Start date: September 2002
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to assess the performance and safety of two reduced sirolimus doses on the Bx VELOCITY Balloon-Expandable stent, mounted on the Raptorâ rapid exchange (RX) Stent Delivery System (SDS) in patients with de novo native coronary artery lesions.

NCT ID: NCT00233714 Completed - Clinical trials for Coronary Artery Disease

Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions

3D
Start date: May 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The main objective of this study is to assess safety and effectiveness of double dose sirolimus-eluting Bx VELOCITY stents in diabetic patients with a de novo native coronary lesion, as compared to single dose sirolimus-eluting Bx VELOCITY™ stents.